Karilyn T Larkin, MD
Academic Title: Assistant Professor in the College of Medicine
Research Program: Leukemia and Hematologic Malignancies
About Me
More info forI am a hematologist with specialties in acute myeloid leukemia (AML) and blood and marrow transplant (BMT). I also serve as a clinical instructor at The Ohio State University. After I received my medical degree from Albany Medical College, I completed my residency and fellowship at Ohio State and was delighted to be asked to join the staff at the OSUCCC – James. In 2012, I received Ohio State’s Michael R. Grever Award for Outstanding Clinical Resident in Hematology/Oncology. As a member of the Leukemia and Hematologic Malignancies Program at the OSUCCC – James, my research is focused on developing new therapies for AML, using both immune-therapies and small molecules, and phase I clinical trials. The James is a first-class facility where cutting-edge therapies are developed every day. We learn from one another as we share our findings. It’s an honor to work alongside some of the foremost cancer experts in the world and see the progress we’re making toward eradicating this disease.
Clinical Expertise
More info for- Myelodysplastic Syndromes
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Acute Myeloid Leukemias
- Bone Marrow Transplantation
Where I See Patients
More info forThe Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
460 W. 10th Ave. Columbus, Ohio 43210 800-293-5066 Location InformationEducation & Training
More info forMedical School
- Albany Medical College
47 New Scotland Ave, Albany, NY
Fellowship - Hematology & Oncology
- Ohio State University Wexner Medical Center
700 Ackerman Rd, Columbus, OH
Internship - Internal Medicine
- Ohio State University Wexner Medical Center
700 Ackerman Rd, Columbus, OH
Residency - Internal Medicine
- Ohio State University Wexner Medical Center
700 Ackerman Rd, Columbus, OH
- Albany Medical College
Academic Office & Contact Information
More info forAcademic Office:
Comprehensive Cancer Center 0468
410 W 12th Ave
Columbus, Ohio 43210-1214Phone:
614-346-1416Email:
larkin.76@osu.eduReviews
More info forPatient Satisfaction Review
The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our
Patient Satisfaction Survey page The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.
Publications
More info forOctober 12, 2024Combination ruxolitinib and belumosudil is tolerable and induces responses despite treatment failure as monotherapies.
Caputo J, Peddireddi A, Bhatta S, Huang Y, Bezerra E, Brammer J, Larkin K, Mims A, Vasu S, Wall S, Choe H
Leuk Lymphoma
October 4, 2024Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia.
Stiff A, Fornerod M, Kain BN, Nicolet D, Kelly BJ, Miller KE, Mrózek K, Boateng I, Bollas A, Garfinkle EAR, Momoh O, Fasola FA, Olawumi HO, Mencia-Trinchant N, Kloppers JF, van Marle AC, Hu E, Wijeratne S, Wheeler G, Walker CJ, Buss J, Heyrosa A, Desai H, Laganson A, Hamp E, Abu-Shihab Y, Abaza H, Kronen P, Sen S, Johnstone ME, Quinn K, Wronowski B, Hertlein E, Miles LA, Mims AS, Oakes CC, Blachly JS, Larkin KT, Mundy-Bosse B, Carroll AJ, Powell BL, Kolitz JE, Stone RM, Duarte C, Abbott D, Amaya ML, Jordan CT, Uy GL, Stock W, Archer KJ, Paskett ED, Guzman ML, Levine RL, Menghrajani K, Chakravarty D, Berger MF, Bottomly D, McWeeney SK, Tyner JW, Byrd JC, Salomonis N, Grimes HL, Mardis ER, Eisfeld AK
Nat Genet
June 12, 2024Impact of chronic graft-versus-host disease on non-relapse mortality and survival.
Jiang J, Sigmund AM, Zhao Q, Elder P, Vasu S, Jaglowski S, Mims A, Choe H, Larkin K, Wall S, Grieselhuber N, William B, Penza S, Benson DM, Efebera YA, Sharma N
Leuk Lymphoma
March 4, 2024The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling.
Marr AR, Halpin M, Corbin DL, Asemelash Y, Sher S, Gordon BK, Whipp EC, Mitchell S, Harrington BK, Orwick S, Benrashid S, Goettl VM, Yildiz V, Mitchell AD, Cahn O, Mims AS, Larkin KTM, Long M, Blachly J, Woyach JA, Lapalombella R, Grieselhuber NR
Exp Hematol Oncol
November 28, 2023Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG).
Ozga M, Nicolet D, Mrózek K, Yilmaz AS, Kohlschmidt J, Larkin KT, Blachly JS, Oakes CC, Buss J, Walker CJ, Orwick S, Jurinovic V, Rothenberg-Thurley M, Dufour A, Schneider S, Sauerland MC, Görlich D, Krug U, Berdel WE, Woermann BJ, Hiddemann W, Braess J, Subklewe M, Spiekermann K, Carroll AJ, Blum WG, Powell BL, Kolitz JE, Moore JO, Mayer RJ, Larson RA, Uy GL, Stock W, Metzeler KH, Grimes HL, Byrd JC, Salomonis N, Herold T, Mims AS, Eisfeld AK
Leukemia
September 4, 2023Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia.
Bhatnagar B, Zhao Q, Mims AS, Vasu S, Behbehani GK, Larkin K, Blachly JS, Badawi MA, Hill KL, Dzwigalski KR, Phelps MA, Blum W, Klisovic RB, Ruppert AS, Ranganathan P, Walker AR, Garzon R
Leuk Lymphoma
June 22, 2023Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.
Bolaños-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, Elmariah H, Rezvani AR, Gooptu M, Larkin KT, Shaffer BC, El Jurdi N, Loren AW, Solh M, Hall AC, Alousi AM, Jamy OH, Perales MA, Yao JM, Applegate K, Bhatt AS, Kean LS, Efebera YA, Reshef R, Clark W, DiFronzo NL, Leifer E, Horowitz MM, Jones RJ, Holtan SG, BMT CTN 1703 Investigators
N Engl J Med
May 17, 2023Association of social deprivation with survival in younger adult patients with AML: an Alliance study.
Rebechi M, Kohlschmidt J, Mrózek K, Nicolet D, Mims AS, Blachly JS, Orwick S, Larkin K, Oakes CC, Hantel A, Carroll AJ, Blum W, Powell BL, Uy GL, Stone RM, Larson RA, Byrd JC, Paskett ED, Plascak JJ, Eisfeld AK
Blood Adv
November 14, 2022Longitudinal Survival Outcomes in Allogeneic Stem Cell Transplantation: An Institutional Experience.
Jiang J, Sigmund AM, Zhao Q, Elder P, Benson DM, Vasu S, Jaglowski S, Mims A, Choe H, Larkin K, Brammer JE, Wall S, Grieselhuber N, Saad A, Penza S, Efebera YA, Sharma N
Cancers (Basel)
July 5, 2022High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML.
Larkin K, Nicolet D, Kelly BJ, Mrózek K, LaHaye S, Miller KE, Wijeratne S, Wheeler GL, Kohlschmidt J, Blachly JS, Mims AS, Walker C, Oakes CC, Orwick S, Boateng I, Buss J, Heyrosa A, Desai H, Carroll AJ, Blum W, Powell BL, Kolitz JE, Moore JO, Mayer RJ, Larson RA, Stone RM, Paskett ED, Byrd JC, Mardis E, Eisfeld AK
Blood Adv
July 1, 2022What is the role of leukopenia in the assessment of septic arthritis?
Brown CR, Samade R, Lynch D, Mickley J, Larkin KTM, Speeckaert AL
J Orthop
January 1, 2022Impact of Race and Geographic Area of Residence on Outcomes After Allogeneic Stem Cell Transplant.
Sigmund AM, Zhao Q, Jiang J, Elder P, Benson DM, Rosko A, Bumma N, Khan A, Devarakonda S, Vasu S, Jaglowski S, Mims A, Choe H, Larkin K, Brammer J, Wall S, Grieselhuber N, Saad A, Penza S, Efebera YA, Sharma N
Front Oncol
December 21, 2021Acute GVHD, BK hemorrhagic cystitis and age are risk factors for transplant-associated thrombotic microangiopathy in adults.
Vasu S, Bostic MG, Zhao Q, Sharma N, Puto M, Knight S, Scott D, Guzman R, Kromer M, Tackett K, Lind KE, Knill K, Watson E, Wall SA, Saad A, Choe HK, Larkin K, Brammer JE, Jaglowski SM, Penza S, Davies SM, Cataland SR
Blood Adv
November 17, 2021PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in Acute Myeloid Leukemia.
Goswami S, Mani R, Nunes J, Chiang CL, Zapolnik K, Hu EY, Frissora FW, Mo XM, Walker LA, Yan PS, Bundschuh R, Beaver L, Devine RD, Tsai YT, Ventura AM, Xie Z, Chen M, Lapalombella R, Walker AR, Mims AS, Larkin K, Grieselhuber NR, Bennett C, Phelps MA, Hertlein E, Behbehani GK, Vasu S, Byrd JC, Muthusamy N
Blood
October 28, 2021Diagnostic utility of bronchoscopy in newly diagnosed acute leukemia patients.
Koenig KL, Curley TP, Mani S, Keiter A, Zhao Q, Behbehani GK, Bhatnagar B, Blachly JS, Haque TZ, Larkin KTM, Long M, Mims AS, Vasu S, Wall SA, Byrd JC, Lustberg M, Walker AR, Grieselhuber NR
Hematol Oncol
August 9, 2021Optimizing extracellular vesicles' isolation from chronic lymphocytic leukemia patient plasma and cell line supernatant.
Elgamal S, Cocucci E, Sass EJ, Mo XM, Blissett AR, Calomeni EP, Rogers KA, Woyach JA, Bhat SA, Muthusamy N, Johnson AJ, Larkin KT, Byrd JC
JCI Insight
June 27, 2021Outcomes of Bone Marrow Compared to Peripheral Blood for Haploidentical Transplantation.
Sharma N, Faisal MS, Zhao Q, Jiang J, Elder P, Benson DM, Rosko A, Chaudhry M, Bumma N, Khan A, Devarakonda S, Vasu S, Jaglowski S, Mims AS, Choe H, Larkin K, Brammer JE, Wall S, Grieselhuber N, Saad A, Penza S, Sigmund AM, Efebera YA
J Clin Med
June 1, 2021Inhibiting the Inhibitors of Apoptosis: When Two Targets Are Better Than One.
Larkin KTM, Byrd JC
Cancer Discov
May 21, 2021Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq.
Saygin C, Hu E, Zhang P, Sher S, Lozanski A, Doong TJ, Nicolet D, Orwick S, Labanowska J, Skinner JN, Cempre C, Kauffman T, Goettl VM, Heerema NA, Abruzzo L, Miller C, Lapalombella R, Behbehani G, Mims AS, Larkin K, Grieselhuber N, Walker A, Bhatnagar B, Bloomfield CD, Byrd JC, Lozanski G, Blachly JS
Leukemia
May 19, 2021Whole-genome sequencing for myeloid disease: one assay to stratify them all?
Larkin KTM, Byrd JC
Nat Rev Clin Oncol
March 24, 2021Type of prior genotoxic insult determines the genomic characteristics of therapy-related myeloid neoplasms.
Ozga M, Blachly J, Eisfeld AK, Grieselhuber N, Larkin K, Walker A, Bhatnagar B, Behbehani G, Long M, Haque T, Vasu S, Zhao W, Jones D, Byrd JC, Mims AS, Saygin C
Am J Hematol
March 16, 2021Loss of expression of both miR-15/16 loci in CML transition to blast crisis.
Lovat F, Gasparini P, Nigita G, Larkin K, Byrd JC, Minden MD, Andreeff M, Carter BZ, Croce CM
Proc Natl Acad Sci U S A
February 4, 2021Effect of Early Post-Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation.
Sharma N, Zhao Q, Ni B, Elder P, Puto M, Benson DM, Rosko A, Chaudhry M, Devarakonda S, Bumma N, Khan A, Vasu S, Jaglowski S, William BM, Mims A, Choe H, Larkin K, Brammer J, Wall S, Grieselhuber N, Saad A, Penza S, Efebera Y
Cancers (Basel)
November 24, 2020Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS.
Rasor B, Dickerson T, Zhao Q, Elder P, Brammer JE, Larkin K, Jaglowski S, Mims A, Penza S, Vasu S, Wall SA, William B, Saad A, Roddy JVF, Choe H, Puto M
Leuk Lymphoma
October 13, 2020Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome.
Kittai AS, Bond DA, William B, Saad A, Penza S, Efebera Y, Larkin K, Wall SA, Choe HK, Bhatnagar B, Vasu S, Brammer J, Shindiapina P, Long M, Mims A, O'Donnell L, Bhat SA, Rogers KA, Woyach JA, Byrd JC, Jaglowski SM
Blood Adv
September 14, 2020Transducin β-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma.
Youssef Y, Karkhanis V, Chan WK, Jeney F, Canella A, Zhang X, Sloan S, Prouty A, Helmig-Mason J, Tsyba L, Hanel W, Zheng X, Zhang P, Chung JH, Lucas DM, Kauffman Z, Larkin K, Strohecker AM, Ozer HG, Lapalombella R, Zhou H, Xu-Monette ZY, Young KH, Han R, Nurmemmedov E, Nuovo G, Maddocks K, Byrd JC, Baiocchi RA, Alinari L
Haematologica
September 4, 2020Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia.
Underwood B, Zhao Q, Walker AR, Mims AS, Vasu S, Long M, Z Haque T, Blaser BW, Grieselhuber NR, Wall SA, Behbehani GK, Blachly JS, Larkin K, Byrd JC, Garzon R, Wang TF, Bhatnagar B
Int J Hematol Oncol
August 10, 2020A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Saygin C, Larkin K, Blachly JS, Orwick S, Ngankeu A, Gregory CT, Phelps MA, Mani S, Walker A, Garzon R, Vasu S, Walsh KJ, Bhatnagar B, Klisovic RB, Grever MR, Marcucci G, Byrd JC, Blum W, Mims AS
Am J Hematol
March 24, 2020Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.
Lucas F, Larkin K, Gregory CT, Orwick S, Doong TJ, Lozanski A, Lozanski G, Misra S, Ngankeu A, Ozer HG, Sampath D, Thangavadivel S, Yilmaz AS, Rogers KA, Byrd J, Woyach JA, Blachly JS
Blood
Consulting and Related Relationships
More info forAt The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Larkin has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.
- Binaytara Foundation
- Debiopharm
Patient Comments
Excellent
The staff at The James has been absolutely amazing.
Anything higher than Very Good ?! Dr.. Larkin is Exceptional!!
Dr.Karilyn Larkin is my main care giver. She is the absolute best! Not only do I feel cared for, but I feel loved.and valued. She answers my questions honestly and directly. I can always trust her to do what is best for me as a whole person. She understands me; she sees me as a valuable and viable person; she "gets" me.
Dr. Larkin is the BEST!!!